TNFRSF10A and triple-negative breast carcinoma: Coincidently, a recent preclinical study showed that the DR5 agonistic antibody lexatumumab inhibited lymph node and lung metastasis more robustly than the DR4 agonistic antibody mapatumumab in an orthotopic model of triple-negative breast cancer [21].